Yes I read it the same way so the important Qs are
- how much CR/dilution did we just do to get this deal across the line?
- does debt level stay constant or increase?
I expect we will know today/tonight because DR will want to discuss this at his 4:30pm WA time presentation.
One thing is for sure, the market should no longer be looking at CAI as a 50/50 survival proposition. However expensive or otherwise, this deal will mean that CAI is comfortably generating cashflows across the whole company from now on.
- Forums
- ASX - By Stock
- CAI
- Ann: Trading Halt
Ann: Trading Halt, page-9
-
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add CAI (ASX) to my watchlist
(20min delay)
|
|||||
Last
11.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $93.67M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
CAI (ASX) Chart |
Day chart unavailable
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online